Investment Pitches

Pitch Summary:
Zhongji Innolight. Strong demand in 5G infrastructure and cloud computing combined with international expansion efforts continued to fuel revenue growth. We believe the company's profits have the potential to increase due to its role in the AI computing power cycle, amid rising demand for ultrahigh-speed optical modules.

BSD Analysis:
Zhongji Innolight is a critical supplier of optical transceivers used in high-speed data centers and AI networks. As bandwidth demands explode, optics become the bottleneck — and bottlenecks earn pricing power. The shift toward 400G and 800G modules plays directly into its technical strengths. Customer concentration is real, but qualification barriers are higher than outsiders assume. Cyclicality exists, but secular demand keeps raising the floor. Margins expand sharply when volumes recover. Geopolitics add noise, but global data traffic doesn’t slow for politics. This is not consumer tech. It’s the plumbing of AI-scale connectivity.

Pitch Summary:
HD Hyundai Electric Co. Demand for power transformers, switchgear and smart grid solutions drove earnings growth, while U.S. infrastructure investment plans around AI data centers and grid upgrades supported the stock. We believe the company has been well positioned for global trends around electrification and sustainability.

BSD Analysis:
HD Hyundai Electric sits at the heart of a global power infrastructure rebuild that investors are only beginning to appreciate. Grid expansion, renewable integration, data centers, and EV charging all require the transformers and switchgear it supplies. Order books are strong because lead times are long and capacity is constrained. Pricing power improves when utilities can’t wait. Execution matters because project complexity is high. Margins expand meaningfully when utilization tightens. This is not a cyclical industrial rebound play. It’s electrification infrastructure with multi-year visibility. When grids upgrade, Hyundai Electric gets paid.

Pitch Summary:
SK Hynix. Shares rose as demand for artificial intelligence (AI)-related memory remained high amid the generative-AI boom and surging data center investment. Quarterly results were robust, overwhelmingly powered by surging demand for AI components, especially high bandwidth memory, where SK Hynix is a global technology leader.

BSD Analysis:
SK hynix is one of the clearest leverage points to the AI buildout through its dominance in high-bandwidth memory. HBM is no longer optional — advanced accelerators don’t function without it. Supply is tight, qualification is brutal, and hynix sits in pole position. Memory is still cyclical, but this cycle is structurally different because AI demand doesn’t vanish overnight. Capital intensity is extreme, which magnifies both wins and losses. Technology leadership matters more now than ever, and hynix has it. Volatility is guaranteed. This is not a defensive stock. It’s torque backed by real, unavoidable demand.

Pitch Summary:
FANUC. We initiated a position in this leading maker of industrial robots and machine tools. We expect revenue and earnings to accelerate as global automation demand grows in core markets, such as the U.S., supported by reshoring. Recovering industrial investment in China and other end markets should also provide a boost.

BSD Analysis:
FANUC is industrial automation royalty built for cycles, not quarters. Its robots and CNC systems sit at the heart of global manufacturing, where uptime and precision matter more than brand flash. Demand swings violently with capex cycles, but installed base service and replacement demand anchor long-term value. Investors fixate on China slowdowns and miss the inevitability of automation as labor scarcity worsens. Balance sheet strength allows FANUC to wait out downturns without cutting muscle. Software, controls, and robotics reinforce each other into a closed ecosystem. When factories invest again, FANUC captures share quickly. This is manufacturing productivity monetized with patience.

Pitch Summary:
Roche Holding. We expect earnings to inflect positively for the pharmaceuticals and biotechnology company. Roche has a strong pipeline of new drugs and recently received positive testing results for new breast cancer and multiple sclerosis treatments. The company has been navigating a period of slowing growth from legacy drugs.

BSD Analysis:
Roche is what long-term pharmaceutical dominance actually looks like when hype is stripped away. Its diagnostics and pharma businesses reinforce each other, creating data, distribution, and scale advantages most peers can’t replicate. Oncology remains the core cash engine, even as individual drugs cycle through patent cliffs. The pipeline isn’t flashy, but it’s deep and clinically credible — exactly what you want in late-stage pharma. Diagnostics provides steady, recurring cash flow that smooths drug-cycle volatility. Pricing pressure and biosimilars are real, but Roche has navigated them for decades. Capital allocation favors reinvestment and dividends over financial engineering. This is not a momentum biotech. It’s a healthcare infrastructure company with scientific depth and patience built in.

Pitch Summary:
Rakuten Bank. The Japan-based bank’s share price was lower after investors reacted to quarterly results and indications that deposit costs and marketing expenses may inch higher. We continue to believe the bank is poised to benefit from higher growth as the economic backdrop in the country remains supportive.

BSD Analysis:
Rakuten Bank is a digital-first bank embedded inside one of Japan’s largest consumer ecosystems, which changes the unit economics. Customer acquisition is cheap because banking rides on top of e-commerce, payments, and loyalty rather than standalone marketing. Net interest margins benefit from Japan’s slow exit from zero-rate purgatory, even small moves matter. Investors worry about competition and credit risk, but underwriting has been conservative relative to growth. Scale improves profitability quickly once fixed tech costs are absorbed. Regulatory oversight is tight, which actually favors incumbents with data and capital. This is online banking with a real distribution moat, not a fintech experiment.

Pitch Summary:
AstraZeneca. The company’s share price rose after it presented successful phase 3 trial results for a hypertension treatment. Investors were also encouraged after several pharmaceutical companies, including AstraZeneca, agreed to subsidized pricing on key drugs, which avoided worst-case scenarios.

BSD Analysis:
AstraZeneca has quietly become one of the strongest execution stories in global pharma. Its oncology and rare disease franchises are deep, diversified, and still growing. Unlike one-drug wonders, AstraZeneca’s pipeline actually replaces revenue before cliffs arrive. Emerging markets exposure adds growth but also volatility. Pricing pressure exists, but innovation quality keeps payers engaged. Capital allocation balances R&D ambition with financial discipline. Margins expand as newer therapies scale. This is not defensive pharma anymore. It’s innovation-led compounding with global reach.

Pitch Summary:
Amkor Technology. This provider of assembly and testing services to chipmakers has benefited from signs of recovery in end markets and from its growing focus on artificial intelligence packaging solutions. We believe the push to make chips domestically has been beneficial to Amkor as it is one of two companies in the U.S. capable of providing large-scale advanced packaging solutions.

BSD Analysis:
Amkor is a pure-play on advanced semiconductor packaging, a part of the chip value chain gaining importance as scaling slows. Chiplets, AI accelerators, and heterogeneous integration all push more value downstream. The business is cyclical, but the secular trend is undeniable. Customer concentration is high, which magnifies both upside and risk. Capex requirements are heavy, but returns improve when utilization tightens. Pricing power increases as packaging complexity rises. This is not foundry competition — it’s specialization. Amkor works when volumes normalize and technology matters. Volatility is the entry price.

Pitch Summary:
We bought shares of Repligen Corporation, a life science tools supplier to the bioprocessing industry. The company benefits from strong positioning in monoclonal antibodies and fast-growing cell and gene therapy markets. Repligen’s products are embedded in regulated workflows, creating high switching costs and recurring consumables revenue. The company is leveraging real-time process analytics and AI to build a data moat. We believe Repligen can double revenue over five years while expanding EBITDA margins by 1,000 basis points.

BSD Analysis:
Repligen sells critical components to bioprocessing workflows where failure is not tolerated. Its filtration and chromatography tools are embedded deep inside drug manufacturing, creating high switching costs. Growth slowed as biotech funding cooled, exposing the cyclicality beneath the quality. That doesn’t erase the moat — it just resets expectations. Margins remain strong because the products are mission-critical. As biologics pipelines restart, demand snaps back fast. Capital discipline matters more now than expansion. This is not a biotech bet. It’s life-sciences infrastructure with cyclical timing.

Pitch Summary:
We bought shares of Elanco Animal Health Incorporated, which operates in an industry supported by pet ownership growth and food safety trends. Elanco is at an inflection point as its innovation portfolio accelerates, targeting mid-single-digit revenue growth and double-digit EBITDA and EPS growth. Innovation revenue is expected to rise from 10.6% of sales in 2024 to over 22% in 2026. Management targets 200–350 basis points of EBITDA margin expansion and significant deleveraging by 2028. We believe management guidance may prove conservative.

BSD Analysis:
Elanco operates in a defensive healthcare niche where owners spend on animals even when they cut everything else. The problem has never been demand — it’s been execution and balance-sheet baggage. Management is now focused on simplifying the portfolio and paying down debt rather than chasing growth illusions. The product base is broad, but innovation has lagged peers, putting pressure on pricing. That said, the installed base and global distribution still matter. Margins can recover if cost discipline sticks. This is not a high-growth animal health name. It’s a repair-and-stabilize story with upside if expectations stay low. Elanco works only if management stays boring.

Pitch Summary:
We bought shares of Welltower Inc., a healthcare REIT benefiting from favorable senior housing supply-demand dynamics. Demand is driven by rapid growth in the over-80 population while new supply remains constrained. Management sees upside through enhanced asset management, pricing initiatives, and occupancy gains. A constrained financing environment creates attractive acquisition opportunities below replacement cost. Management’s long-term, equity-only compensation structure further aligns incentives with shareholders.

BSD Analysis:
Welltower owns senior housing and healthcare real estate aligned with demographic inevitability. Years of oversupply and labor pressure delayed returns, not demand. Occupancy recovery provides powerful operating leverage as costs stabilize. Investors anchor to past disappointments and miss improving fundamentals. Scale provides negotiating leverage with operators and staffing partners. Balance sheet flexibility enables patience others can’t afford. This is healthcare real estate waiting for demographics to finish the work.

Pitch Summary:
We bought shares of Arcutis Biotherapeutics, Inc., which sells Zoryve for autoimmune dermatologic conditions. Zoryve offers steroid-like efficacy with fewer side effects and chronic usability. Insurance access has expanded, with 80% of commercially insured patients now covered. Approved indications target 30 million U.S. patients, and moderate adoption implies over $3 billion in peak sales. Arcutis is already free cash flow positive with 90% gross margins, positioning it for significant operating leverage.

BSD Analysis:
Arcutis is a dermatology-focused biotech where differentiation is driven by convenience and efficacy, not moonshot science. Topical and oral therapies target large patient populations with chronic conditions. Commercial execution now matters as much as clinical data. Investors price the equity as binary because launch success determines everything. Reimbursement and physician adoption are the gating factors. Capital needs persist until scale emerges. This is execution-heavy biotech with asymmetric outcomes.

Pitch Summary:
We added to the position in Thermo Fisher Scientific Inc., a life sciences tools company offering instruments, consumables, and bioproduction services. End markets for life sciences tools are improving as biotechnology funding rebounds and biopharmaceutical R&D investment stabilizes. Management outlined a framework for gradual organic growth recovery, targeting 3% to 6% revenue growth with mid-to-high single-digit operating income growth through cost management. Longer term, management believes the company can deliver 7%+ organic growth. We view Thermo Fisher as a competitively advantaged business trading at a reasonable valuation after a challenging multi-year period.

BSD Analysis:
Thermo is life sciences infrastructure at global scale, selling picks and shovels to innovation rather than betting on molecules. Biotech funding cycles create revenue noise, but installed base demand never disappears. Recurring consumables and services smooth earnings volatility. Investors focus on short-term deceleration and miss long-cycle compounding. Scale advantages in distribution and manufacturing are unmatched. Capital allocation balances M&A with organic reinvestment. This is scientific infrastructure that outlives funding booms and busts.

Pitch Summary:
Encompass Health Corporation shares declined following disappointing third-quarter same-store discharges, which we attribute to difficult comparisons and the timing of new hospital openings. We believe this was an anomaly and expect trends to normalize with bed additions in the fourth quarter and into 2026. Notably, EBITDA increased 11% on relatively in-line revenue, reflecting strong cost control and labor efficiency. Management raised 2025 guidance and increased its new-bed growth outlook to approximately 4% annually. We remain constructive given demographic tailwinds, expanding joint-venture opportunities, and robust cash flow generation.

BSD Analysis:
Encompass Health is post-acute care infrastructure embedded in the hospital discharge process. Inpatient rehab volumes rebound as deferred care returns with higher acuity. Scale and outcomes matter in reimbursement discussions more than headlines suggest. Investors worry about labor pressure, but utilization recovery offsets wage inflation. Referral networks create real barriers to entry. Cash flow stabilizes quickly once staffing normalizes. This is healthcare throughput economics, not elective care risk.

Pitch Summary:
Doximity, Inc. detracted from performance as the company issued disappointing guidance for the next two quarters. Client discussions indicated uncertainty around how recent policy changes may affect annual budgets, prompting management to take a more measured approach to revenue yet to be booked. Limited visibility and increased competition from emerging peers further pressured sentiment. Given these dynamics, we exited the position.

BSD Analysis:
Doximity owns a verified physician network that is extraordinarily hard to replicate. Engagement remains high because the platform sits inside daily clinical workflows, not social feeds. Advertising budgets fluctuate, but physician attention does not. Investors fixate on growth deceleration and miss margin durability. Hospitals and pharma pay for trusted access, not impressions. The business is asset-light and throws off cash. This is professional attention monetized efficiently, not adtech hype.

Pitch Summary:
Arcellx, Inc. is developing cell therapies for multiple myeloma, including lead candidate anito-cel in partnership with Gilead. Anito-cel is a BCMA-targeted CAR-T therapy showing comparable efficacy with a more benign neurological side-effect profile relative to competitors. Despite encouraging clinical results, the stock detracted from performance following competitive data from Johnson & Johnson. Based on discussions with myeloma specialists, BCMA CAR-T is expected to remain the preferred second-line treatment for many patients. We continue to believe Arcellx’s therapy is meaningfully differentiated on safety and expect shares to appreciate ahead of a potential 2026 launch.

BSD Analysis:
Arcellx is one of the more interesting next-gen CAR-T stories because it’s trying to fix what’s broken, not repeat what already exists. Its cell therapy approach focuses on improved safety, durability, and manufacturability — the real bottlenecks in CAR-T adoption. Early data has been encouraging, but oncology optimism is always fragile. Partnerships with large pharma help de-risk development but don’t eliminate binary outcomes. Commercial success depends on differentiation, not just approval. Cash burn is real, and timelines are long. This is not a platform company yet. It’s a precision bet on better cell therapy execution. High risk, but not unserious.

Pitch Summary:
Teva Pharmaceutical Industries Limited has historically been known for its large generics business but is increasingly focused on growing its innovative pharmaceutical business, which now represents roughly half of the company’s profits. Austedo continues to see strong adoption in a significantly underpenetrated and underdiagnosed tardive dyskinesia market, Ajovy has gained share in chronic migraine, and Uzedy has launched successfully in schizophrenia. In addition, Teva is preparing to launch a long-acting formulation of olanzapine in the schizophrenia market. We are also encouraged by Teva's internally developed duvakitug, now partnered with Sanofi, which has the potential to become a pipeline-in-a-product across multiple autoimmune conditions. Shares rose during the quarter as the outcome of Medicare drug price negotiations for Austedo proved more favorable than investors had feared.

BSD Analysis:
Teva is the definition of a fallen giant that refuses to die. Years of debt, litigation, and generic price collapse crushed the equity — and deservedly so. What’s changed is brutal cost discipline and a renewed focus on cash flow over growth illusions. Generics remain ugly, but stability matters more than heroics. Specialty drugs like Austedo provide a real, higher-quality earnings stream. Legal overhangs are shrinking, freeing up capital and attention. This is not a comeback growth story. It’s a survival-and-repair story with leverage to normalization. If execution holds, the upside is asymmetric from depressed expectations.

Pitch Summary:
Argenx SE is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose as Vyvgart sales meaningfully exceeded investor expectations. Our conversations with management and neurologists continue to reinforce Vyvgart’s value as an important treatment option with strong long-term growth potential. The drug continues to launch well in generalized myasthenia gravis, and its launch in chronic inflammatory demyelinating polyneuropathy is off to a strong start. Over time, we expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions, supported by pipeline progress and upcoming Phase 3 readouts.

BSD Analysis:
argenx has already done what most biotechs only promise: turn novel science into a real commercial franchise. Its antibody platform has produced drugs that meaningfully change outcomes in rare autoimmune diseases. The lead product is expanding into multiple indications, turning niche success into a platform story. Pricing power is strong because alternatives are limited and efficacy is clear. The pipeline behind the flagship is credible, not speculative. Execution has been disciplined, avoiding the usual biotech sprawl. Cash flow visibility is improving, which changes how risk should be viewed. This is no longer a “hope stock.” It’s a high-quality growth biotech with momentum and substance.

Pitch Summary:
Eli Lilly and Company is a global pharmaceutical company currently best known for its GLP-1 treatments for diabetes and obesity. Shares rose during the quarter as Zepbound’s obesity launch continued to gain strong traction. In addition, investors welcomed the announcement of an agreement with the Trump administration that expands Medicare and Medicaid coverage for Lilly’s obesity drugs, offers lower pricing through Medicaid, and supports continued U.S. drug manufacturing investment. In exchange, Lilly was excluded from any near-term “Most Favored Nations” drug pricing programs or pharmaceutical sector tariffs, improving regulatory certainty. Long term, we view Lilly’s Mounjaro and Zepbound GLP-1/GIP therapies, along with orforglipron, its oral GLP-1, as transformational for diabetic and non-diabetic obese patients, and we expect this drug class to become the standard of care for both diabetes and obesity, ultimately representing a $150 billion-plus market opportunity. In our view, GLP-1 adoption is still in its early innings, and we believe continued uptake will drive a doubling of Lilly’s total revenues by 2030.

BSD Analysis:
Eli Lilly is in the middle of a once-in-a-generation pharma moment, and the market still underestimates how durable it could be. GLP-1 drugs for obesity and diabetes aren’t just blockbusters — they’re reshaping healthcare utilization itself. Demand is constrained by manufacturing, not patients, which is the best problem a drug company can have. Pricing power is enormous, even with political noise swirling in the background. What separates Lilly from past one-drug wonders is the depth of the pipeline behind today’s hits. Capital spending is aggressive but rational, aimed at extending the window of dominance. Margins expand as scale catches up with demand. This is not defensive pharma anymore. It’s growth pharma with real earnings gravity.

Pitch Summary:
Iron Mountain Incorporated contributed positively during the quarter, supported by continued demand for its data center business alongside stable performance in its legacy storage and information management operations. We believe the market is increasingly recognizing Iron Mountain’s transition toward a higher-growth, infrastructure-like cash flow profile, as the data center platform scales and becomes a larger contributor to earnings and valuation.

BSD Analysis:
Iron Mountain monetizes data gravity in both physical and digital form. Paper storage sounds obsolete until you realize regulation and litigation keep boxes alive forever. Data centers add a second growth engine without killing the core cash cow. Investors still frame Iron Mountain as legacy storage and miss the hybrid model. Switching costs are real because compliance risk isn’t theoretical. Cash flow remains sticky and contract-driven. This is boring infrastructure paid by inertia and regulation — two forces that never go away.